Please ensure Javascript is enabled for purposes of website accessibility

Why GW Pharmaceuticals' Shares Dropped 13.4% in August

By Todd Campbell – Sep 6, 2016 at 5:40PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Mounting losses weighed down investor optimism last month.

Image source: GW Pharmaceuticals PLC.

What happened

After reporting fiscal third-quarter financial results on Aug. 9 and updating investors on its progress on developing marijuana-derived medicines, shares in GW Pharmaceuticals PLC (GWPH) fell 13.4% in August, according to S&P Global Market Intelligence.

So what 

GW Pharmaceuticals is conducting a flurry of research into medicine derived from the chemical cannabinoids found in marijuana plants. Sales of the company's only approved marijuana medicine, Sativex, which is used to treat multiple sclerosis spasticity, are tepid, and as a result, GW Pharmaceuticals continues to lose money.

Its fiscal third-quarter revenue was about $3.1 million, down from $11.55 million last year, at current exchange rates. The drop-off in revenue is due to lower collaboration revenue from Otsuka following the shuttering of a program evaluating Sativex's use as a cancer pain therapy last year. Slightly offsetting that decline in collaboration revenue was a $500,000 increase in Sativex sales to $2 million.

The company spent $34.4 million on research and development last quarter, up from $28 million least year. Most of the increase in R&D spending was due to phase 3 studies of Epidiolex, a purified formulation of the cannabinoid CBD that GW Pharmaceuticals is evaluating as a treatment for rare forms of epilepsy.

Overall, GW Pharmaceuticals lost $16.4 million last quarter.

Now what

Sativex's sales are clocking in at an annualized pace of only about $8 million, so GW Pharmaceuticals $1.9 billion market cap is tied less to Sativex's potential than it is to Epidiolex's potential.

The company reported results earlier this year from two trials studying Epidiolex, and in both instances, epilepsy patients saw a substantial drop in monthly seizure rates. GW Pharmaceuticals is still waiting for data from two more epilepsy trials (one in Dravet syndrome and the other in Lennox-Gastaut syndrome), and if those trials are also positive, then a Food and Drug Administration filing for Epidiolex's approval could occur 2017.

There's a big need for new alternatives because many patients with rare forms of epilepsy don't respond to current treatment options. However, investors should remember that the patient population Epidiolex is targeting is small. Investors should also remember that there's no guarantee that the remaining two trials will back up the data that's already been released. Data from the Lennox-Gastaut trial is expected before the end of this quarter and the company hasn't said precisely when the Dravet syndrome results will be available.

Overall, GW Pharmaceuticals has a healthy $254 million cash stockpile, but it's spending heavily and that means it's going to keep losing money for a while. Undeniably, Epidiolex is the company's best shot at a commercial success so far, but with question marks remaining, GW Pharmaceuticals is still a risky bet.  

Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. Like this article? Follow him on Twitter where he goes by the handle @ebcapital to see more articles like this. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

GW Pharmaceuticals plc Stock Quote
GW Pharmaceuticals plc
GWPH

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
342%
 
S&P 500 Returns
107%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.